This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rice, P. L. Articles by Ahnen, D. J. Search for Related Content PubMed PubMed Citation Articles by Rice, P. L. Articles by Ahnen, D. J.

Sulindac Sulfide Inhibits Epidermal Growth Factor-induced Phosphorylation of Extracellular-regulated Kinase 1/2 and Bad in Human Colon Cancer Cells¹

Division of Gastroenterology, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262 [P. L. R., D. J. A.]; University of Colorado Cancer Center, Denver, Colorado 80262 [P. L. R., M. W., D. J. A.]; and Department of Veterans Affairs Medical Center, Denver, Colorado, 80220 [P. L. R., S. S., K. S. B., L. J. D., D. J. A.]

Colorectal cancer is the second leading cause of cancer death in the United States. Nonsteroidal anti-inflammatory drugs including sulindac are promising chemopreventive agents for colorectal cancer. Sulindac and selective cyclooxygenase (COX)-2 inhibitors cause regression of colonic polyps in familial polyposis patients. Sulindac induces apoptotic cell death in cancer cells in vitro and in vivo. In tumor cells, activation of extracellular-regulated kinase (ERK) 1/2 results in phosphorylation of several ERK1/2 effectors, including the proapoptotic protein Bad. Phosphorylation of Ser112 by ERK1/2 inactivates Bad and protects the tumor cell from apoptosis. Sulindac metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit ERK1/2 phosphorylation in human colon cancer cells. In this study we show that epidermal growth factor (EGF) strongly induces phosphorylation of ERK1/2 and Bad in HT29 colon cancer cells. EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with U0126, a selective MAP kinase kinase (MKK)1/2 inhibitor. Similarly, pretreatment with sulindac sulfide blocks the ability of EGF to induce ERK1/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels. The ability of sulindac to block ERK1/2 signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells.

This article has been cited by other articles:

				L. A. Stark, K. Reid, O. J. Sansom, F. V. Din, S. Guichard, I. Mayer, D. I. Jodrell, A. R. Clarke, and M. G. Dunlop Aspirin activates the NF-{kappa}B signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer Carcinogenesis, May 1, 2007; 28(5): 968 - 976. [Abstract] [Full Text] [PDF]

				J.-Y. Liou, D. Ghelani, S. Yeh, and K. K. Wu Nonsteroidal Anti-inflammatory Drugs Induce Colorectal Cancer Cell Apoptosis by Suppressing 14-3-3{varepsilon} Cancer Res., April 1, 2007; 67(7): 3185 - 3191. [Abstract] [Full Text] [PDF]

				P. Sterpetti, L. Marucci, C. Candelaresi, D. Toksoz, G. Alpini, L. Ugili, G. S. Baroni, G. Macarri, and A. Benedetti Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G624 - G632. [Abstract] [Full Text] [PDF]

				P. L. Rice, S. L. Peters, K. S. Beard, and D. J. Ahnen Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways. Mol. Cancer Ther., March 1, 2006; 5(3): 746 - 754. [Abstract] [Full Text] [PDF]

				W. K.K. Wu, H. P.S. Wong, S. W. Luo, K. Chan, F. Y. Huang, M. K.C. Hui, E. K.Y. Lam, V. Y. Shin, Y. N. Ye, Y. H. Yang, et al. 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone from Cigarette Smoke Stimulates Colon Cancer Growth via {beta}-Adrenoceptors Cancer Res., June 15, 2005; 65(12): 5272 - 5277. [Abstract] [Full Text] [PDF]

				P. L. Rice, K. S. Beard, L. J. Driggers, and D. J. Ahnen Inhibition of Extracellular-signal Regulated Kinases 1/2 Is Required for Apoptosis of Human Colon Cancer Cells In vitro by Sulindac Metabolites Cancer Res., November 15, 2004; 64(22): 8148 - 8151. [Abstract] [Full Text] [PDF]